An in vitro MAPK inhibitor withdrawal rebound model was generated using the patient-derived, PXA-like cell line BT-40 (BRAFV600E, CDKN2Adel). Using this model, we investigated potential cellular intrinsic and extrinsic mechanisms involved in rebound growth in pLGG through multi-omics analysis (RNAseq, phospho-/proteomics).